Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458918 | 0.87 | TGM2 (0.42) | TGM2MAPTALDH1A1USP2CYP3A4 | |
| SCHEMBL2458923 | 0.87 | TGM2 (0.42) | TGM2MAPTALDH1A1USP2CYP3A4 | |
| SCHEMBL2888631 | 0.87 | TGM2 (0.42) | TGM2MAPTALDH1A1USP2CYP3A4 | |
| SCHEMBL2891734 | 0.87 | TGM2 (0.42) | TGM2MAPTALDH1A1USP2CYP3A4 | |
| SCHEMBL1029103 | 0.85 | TGM2 (0.47) | TGM2MAPTALDH1A1USP2CYP3A4 | |
| SCHEMBL3243450 | 0.82 | NOD1 (0.46) | TGM2SLC6A5 | |
| SCHEMBL3311510 | 0.82 | NOD1 (0.46) | TGM2SLC6A5 | |
| SCHEMBL13679273 | 0.82 | NOD1 (0.46) | TGM2SLC6A5 | |
| SCHEMBL1445653 | 0.82 | SMN1; SMN2 (0.44) | TGM2MAPTALDH1A1USP2CYP3A4 | |
| SCHEMBL21062505 | 0.81 | CTSS (0.43) | TGM2SIRT2SIRT1FOLH1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | TGM2 541/4885MAPT 4119/4885ALDH1A1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.